Varian Medical Systems — Q2 FY2005 Earnings Presentation
12 slides from Varian Medical Systems's earnings presentation, Apr 27, 2005
Slide 1: Q2 FY2005 Overview
Slide 2: Forward-Looking Statements
Forward-Looking Statements Except for historical information, the information that follows contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include the matters desc
Slide 3: Q2 FY05 Summary
Q2 FY05 Summary Orders Up Revenues Up Backlog Up 13% 9% 20% * Operating Earnings 23% (% of revenue) EPS Up 26%
Slide 4: Oncology Net Order Growth Rates
Oncology Net Order Growth Rates North America and International Markets 50.00% 40.00% so00% HY fe 4 20.00% 4m | 10.00% Lath, 0.00% 10.00% -20.00% Trailing 12 Months as of April 4, 2005 Comparisons prior to 1999 based on non-published internal data
Slide 5: Oncology Global Net Order Growth Rate
Oncology Global Net Order Growth Rate 30.00% 25.00% 20.00% 16.00% 10.00% fits 5.00% 0.00% -500% -10,00% Traling 12 Months as of April 4, 2005 TARTAN
Slide 6: Oncology Net Order Growth Dollars
Oncology Net Order Growth Dollars 1,400,000 4,200,000 4,000,000 800,000 600,000 } 400,000 4 200,000 0 Trailing 12 Months as of April 4, 2005 Comparisons prior to 1999 based on non-published internal data
Slide 7: Global Share of Radiation Oncology Orders
Global Share of Radiation Oncology Orders Elekta Siemens Tomo Others Estimate as of April 1, 2005
Slide 8: On-Board Imaging on Trilogy or Clinac Accelerators
On-Board Imaging on Trilogy or Clinac Accelerators 50+ installations complete or in progress around world * Clinical now
Slide 9: 3D Cone Beam Imaging on Varian On-Board Imager
3D Cone Beam Imaging on Varian On-Board Imager «In Clinical Use + Seven sites installed
Slide 10: Q2 FY05 Financial Results
Net Orders Revenues Gross Margin R&D SG&A Operating Earnings Operating Earnings (% of revenue) EPS Q2 FY05 VMS os XRP Other 395 13% 329 14% 54 8% 12 30% 351 9% 289 7% 50 20% 11 26% 43% 44% 33% 48% 20 51 $79 23% $0.39 +26% (138M diluted shares)
Slide 11: Q2 FY05 Balance Sheet / Cash Flow
Q2 FY05 Balance Sheet / Cash Flow + Conservative balance sheet - $372M cash and marketable secs. - $ 61M total debt - $638M shareholder equity . Seen! $56M on stock buy-back and $13M for Sigma icro acquisition in the quarter. + *DSO 80 days — up 7 days from year-ago qtr. + Strong cash flow - $69M ca
Slide 12: Fiscal 2005 Outlook
Fiscal 2005 Outlook (As of end of Second Quarter, Fiscal 2005) + Estimated Revenue Growth at ~ 13% + Estimated EPS Growth Approaching ~ 26% Varian updates its outlook once per quarter when it reports financial results. This information Js for reference purposes only and is not an affirmation of or a
Varian Medical Systems — Q2 FY2005 Earnings Presentation on 6ix